A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Fase: Phase I-II clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Repotrectinib
Patologie: Advanced Solid Tumours
ClinicalTrials.gov: Read the details about clinical trials
PI: Dr.ssa Arsela Prelaj
He may participate in this trial if he has a locally advanced solid tumour (i.e. a cancer that has spread from its initial site to the surrounding area) or a metastatic solid tumour (a cancer that has spread from its initial site to other parts of the body). In addition, his tumour could have a rearrangement (alteration) of genes that play a role in tumour development, such as ROS1, NTRK1, NTRK2 or NTRK3.
The investigational drug is called repotrectinib and is currently being studied as a possible treatment for advanced or metastatic solid tumours with such DNA alterations.
Last update: 20/05/2025